Pancreatic Cancer

About Pancreatic Cancer Clinical Trials (Click to Open)

Join Pancreatic Cancer Clinical Trials

Pancreatic Cancer Clinical TrialsGeneral Purpose:

If you have been diagnosed with pancreatic cancer, you may be wondering why you developed it in the first place. Although many prominent risk factors for pancreatic cancer have been identified – including smoking, diabetes, family history, and obesity – many people develop pancreatic cancer who have no risk factors at all. Pancreatic cancer clinical trials

Fortunately, research is underway with the goal of gaining a better understanding of how and why pancreatic cancer develops or doesn’t develop in people both with, and without, known risk factors.

Additionally, researchers are also working to develop newer and more effective methods of screening and diagnosis for pancreatic cancer, so that tumors can be detected at an earlier stage when they are more likely to respond to treatment.

What Will Pancreatic Cancer Clinical Trials Be Like?

When participating in a pancreatic cancer clinical trial, there are a few basic tests and procedures you may receive; however, the ultimate design of the particular study will determine which specific procedures you will undergo. Some of the following tests and procedures may be used during pancreatic cancer clinical trials:

  • Physical exam
  • Abdominal ultrasound
  • Computed tomography (CT scan, or “CAT scan”) or magnetic resonance imaging Pancreatic Cancer Clinical Trials(MRI) scans. These imaging procedures are non-invasive and provide detailed pictures of areas inside your body.
  • Positron emission tomography (PET) scan, which is an imaging procedure that uses a radioactive sugar injected into the blood through a vein in the arm. This substance attaches to cancer cells in the body, making them visible when viewed by a special camera.
  • Biopsy
  • If the study is evaluating a new type of medication or vaccine, blood and/or urine tests may be performed to monitor how your body metabolizes the medication or how effectively your body has responded to the vaccine.
  • Quality of life assessments to evaluate how your cancer is impacting your ability to perform activities of daily living.
  • Pain assessments

Typical Protocol for Pancreatic Cancer Clinical Trials:

Current research is focused on new ways to detect and treat pancreatic cancer, as well as to develop more effective options for pain management and control of other symptoms. Genetic studies are also underway to gain a better understanding of how and why pancreatic cancer develops in some individuals but not in others. Examples of possible Pancreatic Cancer Clinical Trialsclinical trials include:

  • A clinical trial designed to determine if a newly-developed drug that interferes with a cancer cell’s ability to grow can help patients with advanced pancreatic cancer live longer.
  • A clinical trial designed to determine if a combination of surgery followed by chemotherapy (known as adjuvant chemotherapy) is more effective at preventing the recurrence of pancreatic cancer than treatment with surgery alone.
  • A clinical trial designed to determine if standard chemotherapy given in combination with a newly developed chemotherapy drug is more effective than standard chemotherapy at a) decreasing the size of the pancreatic tumor following treatment and b) producing fewer side effects, including pain. Patients in this study might also be monitored to see which therapy has a greater (and more negative) impact on their quality of life.
  • A long-term clinical trial designed to determine if otherwise healthy individuals who smoke and eat a high fat diet, and who also have a family history of pancreatic cancer, have a higher risk of developing the disease than those who do not have that specific combination of risk factors.

A brief word about randomized trials and placebos:

Many clinical trials involve the comparison of an investigational treatment to a “standard” treatment. Some studies determine which therapy a patient receives through a process known as randomization, in which patients are randomly assigned to receive either the investigational treatment or the standard treatment.

On occasion, with pancreatic cancer clinical trials, a trial will investigate the use of a Pancreatic Cancer Clinical Trialsstandard treatment plus a new drug compared to standard treatment plus a placebo. Placebos are inactive or “sham” treatments that are identical in appearance to the active treatment but have no therapeutic value.

Placebos are necessary to help determine if adverse effects that occur during the clinical trial are the result of the investigational treatment or due to some other factor. They also allow researchers to measure the effects of the active treatment and observe what would have happened without it.

In rare instances where no standard therapy exists, or when a new drug is being evaluated for the first time in a specific cancer, the investigational treatment might be compared to a placebo alone. In these types of trials, those patients who are randomized to the placebo group do not receive an active treatment.

This is rarely done in cancer clinical trials; however it may occasionally be necessary from a scientific standpoint. Placebo-only trials will only be done when ethically appropriate and when patients have been adequately informed that they may end up receiving the placebo rather than the active treatment.

It is very important to note, however, that no one should ever participate in such a placebo trial when there is a widely available and highly effective standard treatment already in existence for their particular type of cancer and clinical situation.

Trial Eligibility and Medical Information Needed:

The type of clinical trial you may be eligible for often depends on many factors, including your disease stage, treatment history, and a variety of clinical findings. Therefore, it is important to know many details pertaining to your specific diagnosis when searching for clinical trials. Examples of the details you will want to have on hand include:

  • The name, location, size, stage, and cell type of your cancer, as well as the locations of any metastases you have. Also know these details for any prior cancer you have had.
  • Know your performance status, which estimates how well you perform normal activities of daily living. Examples: Karnofsky Performance Scale (KPS) and the ECOG scale.
  • Know your treatment history, including chemotherapy, radiation therapy, immunotherapy, and/or surgery.
  • Know your blood cell counts, liver function test results, and kidney function test results.

Suggested Search Terms:

“pancreatic cancer treatment,” “pancreatic cancer chemotherapy,” “pancreatic cancer radiation therapy,” “pancreatic cancer pain management,” “pancreatic cancer surgery,” “advanced pancreatic cancer,” “pancreatic cancer screening,” “metastatic pancreatic cancer,” “pancreatic cancer genetics,” “pancreatic cancer family history,” “pancreatic cancer symptoms,” “pancreatic cancer diet,” “pancreatic cancer smoking,” and “pancreatic cancer alcohol.”

Current Search Term:

“Pancreatic Cancer”

Add Comments or Questions



Phase II Study of NGC-Triple Regimen in Potentially Resectable Pancreatic Cancer Patients


Condition:   Resectable Pancreatic Cancer
Intervention:   Drug: NGC-Triple regimen
Sponsors:   Pancreatic Cancer Research Team;   Celgene Inc
Not yet recruiting


Combination of Radiation Therapy and Anti-PD-1 Antibody in Treating Patients With Pancreatic Cancer


Condition:   Pancreatic Cancer
Interventions:   Radiation: Radiation;   Drug: Anti-PD-1 Antibody
Sponsor:   Shixiu Wu
Recruiting


Study of Gemcitabine, Nab-paclitaxel, and Ficlatuzumab (AV-299) in Patients With Advanced Pancreatic Cancer


Condition:   Pancreatic Cancer
Interventions:   Drug: Gemcitabine;   Drug: Nab-paclitaxel;   Drug: Ficlatuzumab
Sponsors:   Dana-Farber Cancer Institute;   AVEO Pharmaceuticals, Inc.
Not yet recruiting


BIOmarkers in Patients With Pancreatic Cancer ("BIOPAC")


Condition:   Pancreatic Cancer
Intervention:  
Sponsor:   Herlev Hospital
Recruiting


TAA Specific Cytotoxic T Lymphocytes in Patients With Pancreatic Cancer


Condition:   Pancreatic Cancer
Intervention:   Biological: multiTAA specific T cells
Sponsors:   Baylor College of Medicine;   Center for Cell and Gene Therapy, Baylor College of Medicine;   Harris Health System;   The Methodist Hospital System;   Pancreatic Cancer Action Network;   The V Foundation for Cancer Research
Not yet recruiting


RX-3117 in Combination With Abraxane® in Subjects With Metastatic Pancreatic Cancer


Condition:   Metastatic Pancreatic Cancer
Intervention:   Drug: RX-3117
Sponsor:   Rexahn Pharmaceuticals, Inc.
Recruiting


Diet and Exercise After Pancreatic Cancer


Condition:   Pancreatic Cancer
Interventions:   Behavioral: Diet Only;   Behavioral: Diet + Exercise
Sponsor:   University of Alabama at Birmingham
Recruiting


Safety and Efficiency of γδ T Cell Against Pancreatic Cancer


Condition:   Pancreatic Cancer
Interventions:   Procedure: Cryosurgery or IRE surgery;   Biological: γδ T cell;   Other: γδ T cells/ A Cryosurgery or IRE
Sponsors:   Fuda Cancer Hospital, Guangzhou;   Jinan University Guangzhou
Recruiting


A Phase II, International Open Label Trial of Minnelide™ in Patients With Refractory Pancreatic Cancer


Condition:   Pancreatic Cancer
Intervention:   Drug: Minnelide
Sponsors:   Queen Mary University of London;   Minneamrita Therapeutics LLC;   Barts & The London NHS Trust;   Translational Genomics Research Institute
Recruiting


Systematic Hereditary Pancreatic Cancer Risk Assessment and Implications for Personalized Therapy


Condition:   Pancreatic Cancer
Intervention:  
Sponsors:   Dana-Farber Cancer Institute;   National Cancer Institute (NCI)
Not yet recruiting


Clinical Trial Phase I for Theragene in Combination With Chemotherapy for the Locally Advanced Pancreatic Cancer


Condition:   Pancreatic Cancer
Intervention:   Biological: Theragene®,Ad5-yCD/mutTKSR39rep-ADP
Sponsors:   Seoul National University Hospital;   NewGenPharm Inc.
Recruiting


A Clinical Research About Using Irreversible Electroporation to Treat Locally Advanced Pancreatic Cancer


Condition:   Pancreatic Cancer
Intervention:   Device: Irreversible Electroporation (IRE) System
Sponsor:   National Taiwan University Hospital
Active, not recruiting


FIrst Line Treatment of Metastatic Pancreatic Cancer: Sequential Nab-paclitaxel + Gemcitabine/FOLFIRI.3 VS Nab-paclitaxel + Gemcitabine


Condition:   Metastatic Pancreatic Cancer
Interventions:   Drug: FOLFIRI.3;   Drug: nab-paclitaxel+ gemcitabine
Sponsors:   Federation Francophone de Cancerologie Digestive;   UNICANCER;   GERCOR - Multidisciplinary Oncology Cooperative Group
Active, not recruiting


IORT Followed by CCRT or SBRT for Locally Advanced Pancreatic Cancer


Condition:   Pancreatic Cancer
Interventions:   Radiation: Concurrent chemoradiotherapy(CCRT);   Radiation: Stereotactic Radiotherapy(SBRT);   Drug: S-1
Sponsor:   Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Recruiting


BPM31510 Administered Intravenously With or Without Gemcitabine in Advanced Pancreatic Cancer Patients


Condition:   Pancreatic Cancer
Interventions:   Drug: BPM31510 Nanosuspension Injection;   Drug: Gemcitabine
Sponsor:   Berg, LLC
Recruiting


First-line Metastatic Pancreatic Cancer : FOLFIRINOX +/- LV5FU2 in Maintenance Versus Firgem


Condition:   Metastatic Pancreatic Cancer
Interventions:   Drug: FOLFIRINOX;   Drug: LV5FU2;   Drug: FOLFIRI.3;   Drug: Gemcitabine
Sponsor:   Federation Francophone de Cancerologie Digestive
Active, not recruiting


Gemcitabine/Nab-Paclitaxel With HIGRT in Resectable Pancreatic Cancer


Condition:   Resectable Pancreatic Cancers
Interventions:   Drug: Gemcitabine/nab-Paclitaxel;   Radiation: Radiation therapy;   Other: Sugical resection;   Drug: Adjuvant chemotheapy
Sponsor:   Duke University
Recruiting


Effects of Folfirinox and Stereotactic Body Radiation Therapy for Advanced Pancreatic Cancer


Condition:   Pancreatic Cancer Non-resectable
Interventions:   Drug: Folfirinox;   Radiation: Stereotactic Body Radiation Therapy
Sponsors:   University of Louisville;   James Graham Brown Cancer Center
Recruiting


Quality of Life Study in Patients With Locally Advanced or Metastatic Pancreatic Cancer Treated With Gemcitabine in Combination With Nab-paclitaxel


Condition:   Pancreatic Cancer
Interventions:   Drug: Abraxane (nab-paclitaxel);   Drug: Gemcitabine
Sponsors:   Universitaire Ziekenhuizen Leuven;   Celgene Corporation
Active, not recruiting


Dose Escalation Study of OMP-54F28 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Previously Untreated Stage IV Pancreatic Cancer


Conditions:   Pancreatic Cancer;   Stage IV Pancreatic Cancer
Intervention:   Drug: OMP-54F28, Nab-Paclitaxel and Gemcitabine
Sponsor:   OncoMed Pharmaceuticals, Inc.
Active, not recruiting


A Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Previously Untreated Stage IV Pancreatic Cancer


Conditions:   Pancreatic Cancer;   Stage IV Pancreatic Cancer
Interventions:   Drug: Vantictumab;   Drug: Nab-Paclitaxel;   Drug: Gemcitabine
Sponsor:   OncoMed Pharmaceuticals, Inc.
Active, not recruiting


Short Course Radiation Therapy With Proton or Photon Beam Capecitabine and Hydroxychloroquine for Resectable Pancreatic Cancer


Condition:   Pancreatic Cancer
Interventions:   Drug: Capecitabine;   Drug: Hydroxychloroquine;   Radiation: Proton or Photon Radiation Therapy
Sponsor:   Massachusetts General Hospital
Active, not recruiting


Hydroxychloroquine in Previously Treated Patients With Metastatic Pancreatic Cancer


Condition:   Pancreatic Cancer
Intervention:   Drug: Hydroxychloroquine
Sponsors:   Dana-Farber Cancer Institute;   Brigham and Women's Hospital;   Massachusetts General Hospital
Completed


Evaluate the Efficacy and Safety of Activated T-lymphocyte Cell Therapy in Advanced Pancreatic Cancer


Condition:   Pancreatic Cancer
Intervention:   Biological: Activated T lymphocyte
Sponsor:   Green Cross Cell Corporation
Completed


Gemcitabine and Erlotinib in Treating Patients With Metastatic or Recurrent Pancreatic Cancer


Condition:   Pancreatic Cancer
Interventions:   Drug: Erlotinib;   Drug: gemcitabine
Sponsors:   University of California, Davis;   National Cancer Institute (NCI);   Genentech, Inc.
Completed

Refine Your Search Advanced Search